Spots Global Cancer Trial Database for portal vein thrombosis
Every month we try and update this database with for portal vein thrombosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neo-TACE-HAIC for PVTT-HCC | NCT04181931 | Hepatocellular ... Portal Vein Thr... | neo-TACE-HAIC+S... Surgery alone | 18 Years - 75 Years | Sun Yat-sen University | |
| Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery | NCT01690715 | Hepatocellular ... Portal Vein Thr... Hepatic Portal ... | - | Hospital Sirio-Libanes | ||
| EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications | NCT03477149 | Varicocele Endoleak Portal Vein Thr... Bleeding Angiomyolipoma | Easyx | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis | NCT04771988 | Hepatocellular ... | yttrium-90 radi... | 18 Years - | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma | NCT03535259 | Hepatocellular ... | concurrent sora... | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC | NCT04791176 | Hepatocellular ... Radiotherapy Lenvatinib | concurrent lenv... | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT | NCT05166239 | Hepatocellular ... Portal Vein Thr... | HAIC Lenvatinib 1 PD-1 Inhibitors Lenvatinib 2 PD-1 inhibitors... | 18 Years - 80 Years | Peking University | |
| EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications | NCT03477149 | Varicocele Endoleak Portal Vein Thr... Bleeding Angiomyolipoma | Easyx | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Surgical Outcome of HCC With Portal Vein Tumor Thrombosis on the Basis of Risk Scoring | NCT06005883 | Hepatocellular ... Portal Vein Thr... Prognosis | - | Keimyung University Dongsan Medical Center | ||
| Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis | NCT03009461 | HepatoCellular ... Portal Vein Thr... | HAIC Sorafenib | 18 Years - 75 Years | Peking University | |
| Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma | NCT03902678 | Portal Vein Thr... | EUS guided fine... | 18 Years - | Mansoura University | |
| IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation | NCT05339581 | Liver Cancer Liver Transplan... Hepatocellular ... Portal Vein Thr... Radiotherapy; C... | intensity-modul... Pembrolizumab Sintilimab Camrelizumab Tislelizumab Lenvatinib Mesy... | 18 Years - 80 Years | RenJi Hospital | |
| HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT | NCT05166239 | Hepatocellular ... Portal Vein Thr... | HAIC Lenvatinib 1 PD-1 Inhibitors Lenvatinib 2 PD-1 inhibitors... | 18 Years - 80 Years | Peking University | |
| Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism | NCT02585713 | Cerebral Vein T... Deep Vein Throm... Gonadal Thrombo... Hepatic Thrombo... Malignant Neopl... Mesenteric Thro... Metastatic Mali... Portal Vein Thr... Pulmonary Embol... Renal Vein Thro... Splenic Thrombo... Venous Thromboe... | Apixaban Dalteparin Questionnaire A... | 18 Years - | Academic and Community Cancer Research United | |
| TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis | NCT01556282 | Liver Cancer Portal Vein Thr... | TheraSphere | 18 Years - | Emory University | |
| IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation | NCT05339581 | Liver Cancer Liver Transplan... Hepatocellular ... Portal Vein Thr... Radiotherapy; C... | intensity-modul... Pembrolizumab Sintilimab Camrelizumab Tislelizumab Lenvatinib Mesy... | 18 Years - 80 Years | RenJi Hospital | |
| Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism | NCT02585713 | Cerebral Vein T... Deep Vein Throm... Gonadal Thrombo... Hepatic Thrombo... Malignant Neopl... Mesenteric Thro... Metastatic Mali... Portal Vein Thr... Pulmonary Embol... Renal Vein Thro... Splenic Thrombo... Venous Thromboe... | Apixaban Dalteparin Questionnaire A... | 18 Years - | Academic and Community Cancer Research United | |
| Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein | NCT01887717 | Hepatocellular ... | TheraSphere® Sorafenib | 18 Years - | Boston Scientific Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
